GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
CARLSBAD, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial results for the quarter ended September 30, 2020.
Third Quarter 2020 Highlights
“I am extremely proud of the hard work and meaningful progress our team has made during these unprecedented times,” said Scott Mendel, President and Chief Executive Officer. “We continued to see strong demand for both ePlex systems and consumables, including a significant portion of our customers adopting sample-to-answer syndromictesting for the first time. In addition to our commercial successes in the quarter, our manufacturing expansion effort remains on track to meet our capacity goal of 150,000 to 175,000 tests per month by the end of 2020 and 200,000 per month by the end of first quarter of 2021,” concluded Mendel.
These preliminary results are based on management's initial analysis of operations for the quarter ended September 30, 2020 and are subject to further internal review. The company expects to issue full third quarter 2020 financial results in late October.
About GenMark Diagnostics
Safe Harbor Statement
Investor Relations Contact
On Premise Strategies: CBRS and Private LTE